Rigel Pharmaceuticals (RIGL) Other financing activities (2014 - 2026)
Rigel Pharmaceuticals' (RIGL) quarterly Other financing activities came in at $321000.0 in Q1 2026, down 33.68% year-on-year from $484000.0 in Q1 2025, and down 89.04% quarter-over-quarter from $2.9 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Other financing activities (2014 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Other financing activities history runs 13 years deep, the most recent figure standing at $321000.0 for Q1 2026.
- On a quarterly basis, Other financing activities fell 33.68% year-over-year to $321000.0 in Q1 2026; TTM through Mar 2026 was $7.9 million, a 236.5% increase from a year earlier, with the FY2025 full-year figure at $8.1 million, up 312.47% from the prior year.
- Other financing activities slipped to $321000.0 in Q1 2026 per RIGL's latest filing, from $2.9 million in the prior quarter.
- Across five years, Other financing activities topped out at $4.3 million in Q3 2025 and bottomed at $1000.0 in Q1 2023.
- The 5-year median for Other financing activities is $485000.0 (2023), against an average of $847437.5.
- Across the five-year window, Other financing activities tumbled 99.89% in 2023 and soared 8800.0% in 2024, its largest moves.
- Year by year, Other financing activities stood at $585000.0 in 2022, then decreased by 16.92% to $486000.0 in 2023, then surged by 201.44% to $1.5 million in 2024, then soared by 99.86% to $2.9 million in 2025, then sank by 89.04% to $321000.0 in 2026.
- Per Business Quant, the three latest RIGL Other financing activities figures stand at $321000.0 (Q1 2026), $2.9 million (Q4 2025), and $4.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Rigel Pharmaceuticals | 674.25 Mn | 527.57 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 321,000.00 |
| Mar 31, 2026 | 321,000.00 |
| Dec 31, 2025 | 2.93 Mn |
| Dec 31, 2025 | 2.93 Mn |
| Sep 30, 2025 | 4.27 Mn |
| Sep 30, 2025 | 4.27 Mn |
| Jun 30, 2025 | 418,000.00 |
| Jun 30, 2025 | 418,000.00 |
| Mar 31, 2025 | 484,000.00 |
| Mar 31, 2025 | 484,000.00 |
| Dec 31, 2024 | 1.47 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Sep 30, 2024 | 158,000.00 |
| Sep 30, 2024 | 158,000.00 |
| Jun 30, 2024 | 252,000.00 |
| Jun 30, 2024 | 252,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Dec 31, 2023 | 486,000.00 |
| Dec 31, 2023 | 486,000.00 |